Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

This study is testing a combination of two drugs — pucotenlimab (an immunotherapy) and vorolanib (a targeted therapy that cuts off the blood supply to tumors) — given before surgery in patients with clear cell kidney cancer. The goal is to shrink the tumor enough to allow kidney-sparing surgery in cases where that would otherwise be very difficult. **You may be eligible if...** - You are between 18 and 85 years old - You have been diagnosed with clear cell kidney cancer confirmed by biopsy - You are in good health (ECOG score 0–1) and are expected to survive at least 3 months - Your tumor is located in a difficult position or is large enough that kidney-preserving surgery is technically challenging (but still possible) - You are willing to undergo kidney-preserving surgery - Your healthy kidney has reduced function (GFR below 60 mL/min) **You may NOT be eligible if...** - You have received prior treatment for kidney cancer - You have cancer that has spread to lymph nodes or distant organs - You have severe problems with blood counts, liver, or kidney function Talk to your doctor to see if this trial is right for you.